Correction to: In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits
verfasst von:
John D. Sheppard, Paul C. Cockrum, Angela Justice, Mark C. Jasek
In the original publication, units were incorrectly published in the results section as micrograms (µg/mL). The correct units are nanograms (ng/mL). The updated results section and an updated version of Fig. 1 are below.
Aqueous Humor Analyte Pharmacokinetics
The NSAID aqueous humor Cmax of BromSite® BID was 1.7-, 2.2- and 3.7-fold higher than that of BromSite® QD, Prolensa®, and Ilevro®, respectively. The Cmax for Ilevro® occurred at 1 h and for the other three groups at 2 h (Fig. 1a). The Bromsite® BID group had the highest Cmax at 131 ng/mL, followed by Bromsite® QD (77 ng/mL) and Prolensa® (59 ng/mL), while Ilevro® group was much lower at 35 ng/mL. The Cmax in the Bromsite® BID group was statistically significantly higher (p < 0.05) than that of Prolensa® and Ilevro®.
Fig. 1
Concentration–time profile at each matrix. The standard error bars (upper only) are presented. a Aqueous humor concentration–time profile. b Iris ciliary body concentration–time profile. c Sclera concentration–time profile. d Choroid concentration–time profile. e Retina concentration–time profile
×
Anzeige
Open Access
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Correction to: In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits
verfasst von
John D. Sheppard Paul C. Cockrum Angela Justice Mark C. Jasek
